ASE · Financial Statements
AIM ImmunoTech Inc. (AIM) Financial Statements
$0.18
ASE: AIM
Market Cap $7.11M
Overview Financials Dividend AIM ImmunoTech Inc. most recently reported annual revenue of $0, net profit of $-14.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
Annual Financials (USD)
Metric 2021 2022 2023 2024 2025 Revenue $0 $0 $0 $0 $0 Operating Profit $-19.0M $-20.0M $-32.0M $-20.0M $-11.0M Net Profit $-19.0M $-19.0M $-29.0M $-17.0M $-14.0M EPS $-14.67 $-14.69 $-21.64 $-11.22 $-8.62 Op Margin -13954.1% -14129.6% -15800.0% -11630.6% -11961.4%
Balance Sheet (USD)
Metric 2021 2022 2023 2024 2025 Total Assets $58.0M $40.0M $19.0M $9.0M $6.0M Total Liabilities $1.0M $2.0M $9.0M $10.0M $16.0M Cash $32.0M $27.0M $5.0M $2.0M $1.0M Borrowings $0 $1.0M $1.0M $3.0M $5.0M
Cash Flow (USD)
Metric 2021 2022 2023 2024 2025 Operating Cash Flow $-14.0M $-16.0M $-21.0M $-15.0M $-11.0M Investing Cash Flow $-1.0M $11.0M $-1.0M $5.0M $1.0M Financing Cash Flow $0 $0 $0 $3.0M $0 Net Cash Flow $-6.0M $-5.0M $-22.0M $-4.0M $1.0M Free Cash Flow $-14.0M $-16.0M $-22.0M $-15.0M $-11.0M
Valuation & Return Ratios
Metric Value PEG Ratio 0.00 EV / EBITDA -0.11 FCF Yield -96.19% Quick Ratio 2.11 Interest Coverage -9.72 Return 1Y -96.97% Return 3Y -99.55% Return 5Y -99.87%
Screens featuring this stock